Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted Luvometinib ± Cytarabine in Langerhans Cell Histiocytosis
ChiCTR2600129807Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of luvometinib in Langerhans cell histiocytosis (LCH) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoints: Objective response rate after six cycles of luvometinib induction (BICR) and Incidence of adverse events and serious adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2600129807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129807.